Le Lézard
Classified in: Health
Subject: MAT

Cannvas Lists on the Frankfurt Stock Exchange



Gains Valuable Access to Investors Across the European Union

TORONTO, July 18, 2018 /CNW/ - Cannvas MedTech Inc. ("Cannvas" or the "Company") (CSE: MTEC; Frankfurt: 3CM), a leading business technology company within the cannabis space, is pleased to announce its listing on the Frankfurt Stock Exchange under the trading symbol "3CM". The Frankfurt Exchange is a major international stock exchange and ranks third in terms of global volume of trading behind the New York and NASDAQ stock exchanges. The listing on the Frankfurt Stock Exchange provides Cannvas with broader access to European and other international investors.

Cannvas MedTech Inc. (CNW Group/Cannvas MedTech Inc.)

"Our mandate is to continue to build exceptional shareholder value and the listing on the Frankfurt Stock Exchange gains us valuable access to the European and broader global investment market," said Shawn Moniz, Chief Executive Officer, Cannvas. "The listing is another significant milestone for our young company as we look to expand our technological influence to Germany and Europe and around the globe. We invite all new investors to learn more about our company and about Cannvas.me, a scalable and comprehensive solution for the global cannabis community offering interactive tools and physician-backed content to all audiences who wish to learn about healthcare through cannabis."

The Frankfurt Stock Exchange has more than 250 international trading institutions and more than 4,500 traders. The Frankfurt Stock Exchange accounts for over 90% of the volume of all German stock exchanges and represents a large share of the European market. Investors directly connected to the Frankfurt Stock Exchange represent 35% of the world's investment capital. A listing in Frankfurt also provides a tax advantage to German investors.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

For additional information:

www.cannvasmedtech.com

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

SOURCE Cannvas MedTech Inc.


These press releases may also interest you

at 04:00
DAYTON, Ohio, Dec. 11, 2018 /PRNewswire-PRWeb/ -- An epidemic is sweeping the nation. This rapidly spreading issue is not a disease, infestation or plague, but rather the misuse and dependency on opioid pain medication. According to the Center for...

at 04:00
SALT LAKE CITY, Dec. 11, 2018 /PRNewswire-PRWeb/ -- Nightingale College is excited to announce the authorization to offer nursing education in eight new states, in addition to current operations in Utah, Idaho, and Wyoming. The College is newly...

at 04:00
WATCH THE VIDEO: https://youtu.be/o0-oP8dmwC0 Certain dietary patterns, especially those rich in fruits and vegetables, may help decrease the risk of chronic diseases such as diabetes and cardiovascular disease. Despite campaigns and educational...

at 03:30
STATE COLLEGE, Pa., Dec. 11, 2018 /PRNewswire-PRWeb/ -- INDIGO Biosciences, Inc. (INDIGO), the recognized industry leader in nuclear receptor research, announced the addition of a gene expression assay kit featuring upcyte® hepatocytes to their...

at 03:05
Brain health-focused pharmaceutical company Cerecin, today announced that it is a sponsor for the Alzheimer's Disease Therapeutics: Alternatives to Amyloid Symposium to be held in New York, New York, USA. Dr. Samuel Henderson, Cerecin's Chief...

at 03:02
First-of-its-kind analysis charts Artificial Intelligence research trends across the world, with a focus on China, Europe and the United States, and finds a global 'brain drain' from academia to the private sector  China is growing in importance as...




News published on 18 july 2018 at 08:30 and distributed by: